# E-VIRTUE (NCT06041503)

> Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

No report yet. It can be ordered.

- Drugs tested: enfortumab vedotin; enfortumab vedotin plus pembrolizumab
- Indication: rare genitourinary tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06041503
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Adenocarcinoma of the Bladder; Squamous Cell Carcinoma of the Bladder; Testicular Germ Cell Tumors
- Interventions: Pembrolizumab; Enfortumab vedotin
- Enrollment: 68
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on E-VIRTUE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=e-virtue-nct06041503